



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/20</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/33448</b> <b>(43) International Publication Date:</b> 8 July 1999 (08.07.99)
<b>(21) International Application Number:</b> PCT/EP98/08100 <b>(22) International Filing Date:</b> 11 December 1998 (11.12.98) <b>(30) Priority Data:</b> 97/16402 23 December 1997 (23.12.97) FR <b>(71) Applicant (for all designated States except US):</b> MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D-64293 Darmstadt (DE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SASLAWSKI, Olivier [FR/FR]; 43, rue de Sèze, F-69006 Lyon (FR). ORLANDO, Laurence [FR/FR]; 7, rue Frédéric Mistral, F-69150 Décines (FR). <b>(74) Common Representative:</b> MERCK PATENT GMBH; Postfach, D-64271 Darmstadt (DE).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TABLET FOR INSTANT AND PROLONGED RELEASE OF ONE OR MORE ACTIVE SUBSTANCES <b>(57) Abstract</b> <p>The invention relates to a multilayer tablet for the instant and then prolonged release of active substances comprising at least two superposed layers, characterized in that: a first outer layer is composed of a mixture of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance; a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece			<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>ML</b>	Mali	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MN</b>	Mongolia	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MR</b>	Mauritania	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MW</b>	Malawi	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>MX</b>	Mexico	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NE</b>	Niger	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NL</b>	Netherlands	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NO</b>	Norway	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>NZ</b>	New Zealand		
<b>CM</b>	Cameroon			<b>PL</b>	Poland		
<b>CN</b>	China	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CU</b>	Cuba	<b>KZ</b>	Kazakstan	<b>RO</b>	Romania		
<b>CZ</b>	Czech Republic	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>DE</b>	Germany	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DK</b>	Denmark	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>EE</b>	Estonia	<b>LR</b>	Liberia	<b>SG</b>	Singapore		

## TABLET FOR INSTANT AND PROLONGED RELEASE OF ONE OR MORE ACTIVE SUBSTANCES

5

The invention relates to solid galenic forms of the controlled release tablet type for the instant and then prolonged release of one or more active substances.

10 The importance of such galenic forms is undeniable. The immediate release of an active substance will ensure its practically instant bioavailability, which is particularly desirable in the case of patients suffering from acute conditions.

15 However, in the case of active substances having a short half-life, the therapeutic activity is only temporary. Now, a continuous and regular supply of active ingredient is often necessary for an effective therapy. To this end, numerous immediate- and  
20 prolonged-release systems have been developed.

Reference may be made, for example, to the following patents and applications of the state of the art: WO 96/03111, US 4,990,335, EP 352 190, BE 905 282, EP 106 443, EP 36 350, EP 615 444 and EP 220 670.

25 However, in the prior art systems, the kinetics of release of the active ingredient depend on many factors, such as the enzymatic activity and the pH conditions which vary substantially from one individual to another and for the same individual, depending on  
30 whether they are on an empty stomach or not. Furthermore, the pH conditions vary all along the gastrointestinal tract. Thus, it is difficult to predict in vivo, with precision, the profile for the release of a given substance after administration of  
35 the prior art instant- and prolonged-release systems.

The present invention aims to solve this problem by providing tablets which preserve their characteristics for the release of active substances regardless of the conditions of administration in vivo.

- 2 -

The tablets of the invention provide an excellent reproducibility of the results, while allowing an increased control of the rates of release during the phase of prolonged release of the active ingredient. By using the tablets of the invention, it becomes possible to optimize the supply of the active ingredients in the body while taking into account both the subject's tolerance to the active ingredient and the pharmacokinetic and metabolic profiles of the active ingredient.

Tablets of the invention are, moreover, advantageous from the point of view of the formulation of the active ingredients since a judicious choice of the excipients leads to tablets with high concentrations of active ingredients.

Thus, it is possible to produce tablets with very high doses, having an acceptable size for oral administration.

More precisely, the invention relates to multilayer tablets for the instant and then prolonged release of active substances comprising at least two superposed layers, characterized in that:

- a first outer layer is composed of a mixture of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance;

- a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.

The second layer, which is arranged in contact with the first layer, is either completely enveloped by the first layer, or only partially covered by it.

In the first case, the two layers are concentric.

In the second case, only one of the surfaces of the second layer is in contact with the first layer: in the text which follows, this type of tablet is designated as "containing parallel layers" and the

- 3 -

shape of the tablet is unimportant and is in particular ovoidal. It should be understood that in this case, the two layers have one outer surface, their other surface being in contact with one another.

5           The tablets of the invention are preferably bilayered. However, the invention also encompasses multilayer tablets, as long as they comprise the combination of the first and second layers defined above.

10           For some active ingredients, problems of stability of the active ingredient included in the prolonged-release matrix may exist. In this case, it is advantageous to opt for the preparation of tablets containing concentric layers.

15           The kinetics of release of the active ingredient depend, in each case, on the exact composition of the layer considered. It is by adapting the nature and the quantity of the excipients constituting the two layers that the kinetics of  
20 release can be modulated.

          One characteristic of the first layer is that it disintegrates rapidly at the site of administration. In contrast, the second layer is not biodegradable. Its matrix is inert in the sense that it does not react  
25 with the surrounding medium. The matrix of the second layer retains its physical and chemical integrity throughout the prolonged release of the active ingredient, regardless of the pH variations.

          Since the first layer disintegrates instantly  
30 upon contact with an aqueous medium such as a physiological medium, it is easy to understand why the release of the first active substance is immediate.

          In the case of the second layer and since the matrix constituting it is inert (it does not become  
35 eroded and does not swell in an aqueous medium), the release of the second active substance occurs by lixiviation and diffusion. The surrounding aqueous medium gradually penetrates into the inert porous matrix and then progressively, this aqueous medium

- 4 -

dissolves the active substance dispersed in the inert matrix. The mechanism of diffusion being slow in essence, it can be understood why the release of the active ingredient is prolonged in this case.

5           Whereas the mechanism of disintegration of the first layer does not, or not to any great extent, depend on the nature of the active substance, it is clear that the more or less hydrophilic character of the active substance of the second layer can influence  
10 the kinetics of lixiviation/diffusion.

          However, the invention is not limited as to the nature of the active substances. Each layer may contain a different active ingredient.

          However, according to a specific embodiment of  
15 the invention, the first and second layers comprise the same active substance.

          The active substances may be chosen in particular from any of the following groups (to designate the active substances, the international  
20 nonproprietary names have been adopted):

- medicaments which are active in asthma such as 2-ethoxymethyl-4(3H)-pteridinone and bronchodilators such as theophylline, and/or some anti-inflammatory agents or antihistaminics of the ketotifen type;
- 25 - medicaments which are active in the treatment of diabetes and its related complications of the neurological, nephrological, ocular or vascular type. By way of example, there may be mentioned metformin, hypolipidaemic agents such as fenofibrate or  
30 pravastatin and anti-atheromatous agents in general;
- medicaments which are active in the treatment of alcoholism, such as acamprosate;
- peripheral analgesics, for example para-aminophenol derivatives such as paracetamol, salicylated  
35 derivatives such as aspirin, diflunisal, propionic acid derivatives such as ibuprofen, fenoprofen, ketoprofen, aminoquinoline derivatives such as floctafenine, pyrazolone derivatives such as noramidopyrine;

- 5 -

- central analgesics such as dextropoxyphene, codeine, morphine, pethidine, dextromoramide, buprenorphine, nalbuphine, pentazocine;
- antispasmodics such as tiemonium, difemerine, phloroglucinol, trimebutine, pinaverium, prifinium;
- nonsteroidal anti-inflammatory agents and, for example:
  - . arylpropionic derivatives such as ketoprofen, ibuprofen, naproxen, flurbiprofen, alminoprofen, tiaprofenic acid,
  - . arylacetic derivatives such as diclofenac, fentiazac,
  - . arylcarboxylic derivatives such as fenbufen and etodolac,
  - . anthranilic derivatives or fenamates such as niflumic acid and mefenamic acid,
  - . indole derivatives such as indometacin and oxametacin,
  - . oxicams such as piroxicam, tenoxicam,
  - . pyrazole-containing derivatives such as phenylbutazone,
  - . indene derivatives such as sulindac;
- steroidal anti-inflammatory agents such as corticoids of the prednisone, prednisolone and methylprednisolone type;
- antibiotics of the beta-lactam type, such as penicillins, of the cephalosporin type, such as cefuroxime axetil, of the beta-lactamase inhibitor type, such as clavulanic acid,
- of the aminoglycoside type, such as neomycin, of the macrolide type, such as spiramycin, erythromycin, of the tetracycline type, such as minocycline and doxycycline,
- of the sulfamide type, such as sulfadiazine, of the quinolone type, such as pefloxacin;
- antituberculous agents such as isoniazid, rifampicin, ethambutol, pyrazinamide;

- 6 -

- polyenic antifungal agents such as amphotericin B, nystatin,
- imidazole-containing antifungal agents such as miconazole, ketoconazole, fluconazole, flucytosine, griseofulvin;
- antiviral agents of the type including zidovudine, aciclovir, adamantane such as rimantadine, amantadine, and moroxydine;
- beta-blockers such as acebutolol, celiprolol, atenolol, betaxolol, metoprolol, bisoprolol, propanolol, nadolol, timolol, tertatolol, sotalol, pindolol, penbutolol, carteolol, oxyprenolol, labetalol;
- nitrated derivatives such as isosorbide dinitrate, isosorbide mononitrate, pentaerythrityl tetranitrate, erythrityl tetranitrate;
- antianginals of the sydnonimine type, such as molsidomine and linsidomine,
- cardiotonics such as orciprenaline, or alternatively of the digitalin type, such as digoxin, digitoxin,
- diuretics such as furosemide, bumetanide, clopamide, of the thiazide type such as hydrochlorothiazide, xipamide, of the tienilic acid type, indapamide, cicletanine, spironolactone, canrenone, amiloride, triamteren;
- conversion enzyme inhibitors such as captopril, enalapril, lisinopril, perindopril, quinalapril, ramipril, benazepril;
- calcium inhibitors such as nifedipine, nicardipine, nitrendipine, diltiazem, verapamil, bepridil;
- antihypertensives such as rilmenidine, clonidine, methyldopa, dihydralazine, prazosine, uradipil, minoxidil;
- antiarrhythmics such as quinidine, disopyramide, cibenzoline, propafenone, flecainide, aprindine, nadoxolol, mexiletine, bretylium, amiodarone;
- antiischaemics such as naftidrofuryl, trimetazidine, pentoxyfilline, nicergoline, buflomedil, dihydroergotoxine, dihydroergocristine,



- 7 -

- dihydroergocryptine, moxislyte, raubasine, vincamine, papaverine, nicotinic acid;
- venotonics such as vitamin P;
  - hypotension correctors such as heptaminol;
  - 5 - hormones such as thyroid hormones of the levothyroxine sodium type;
  - medicaments stimulating gastroduodenal motor function, such as cisapride, domperidone;
  - antiemetics such as metoclopramide, metopimazine,
  - 10 aliprazide, odansetron, scopolamine;
  - antiulcer agents such as ranitidine, famotidine, nizatidine, cimetidine, omeprazole, of the antiulcer prostaglandin type such as misoprostol, sucralfate, aluminium hydroxide;
  - 15 - antidiarrhoeals such as loperamide, diphenoxylate, medicaments promoting bacterial flora and those promoting yeast flora;
  - intestinal antiseptics such as nitrofurantoin;
  - contraceptives such as oestroprogestogens;
  - 20 - antianaemic agents such as iron;
  - antihistaminics such as phenothiazine;
  - vitamins such as thiamine, nicotinamide, pyridoxine, biotin, ascorbic acid, cyanocobalamin, retinol, colecalciferol;
  - 25 - antiepileptics such as valproic acid, phenytoin, carbamazepine, ethosuximide, progabide, vigabatrin;
  - antimigraine agents such as oxetorone, indoramine, ergotamine, ergot of rye derivatives such as dihydroergotamine, methysergide, tricyclic derivatives
  - 30 such as pizotifen;
  - anticoagulants such as antivitamin K agents;
  - antiparkinsonians such as levodopa, selegiline, lisuride, bromocriptine, biperiden, orphenadrine, procyclidine, tropatepin, scopolamine;
  - 35 - anxiolytics derived from benzodiazepines such as clotiazepam, tofisopam, oxazepam, alprazolam, lorazepam, bromazepam, prazepam, buspirone, alpidem, hydroxyzine, meprobamate, febarbamate;

- 8 -

- antidepressants such as quinupramine, desipramine, imipramine, clomipramine, amitriptyline, viloxazine, amineptine, fluvoxamine, fluoxetine, tianeptine, oxaflozane, maprotiline, mianserin, trazodone, medifoxamine, toloxatone, IMAOs;
- hypnotics such as zopiclone, zolpidem, and benzodiazepine derivatives such as flunitrazepam, nitrazepam, triazolam, phenothiazine derivatives such as niaprazine, doxylamine, barbiturate derivatives such as butobarbital, amobarbital, phenobarbital;
- normothymics such as lithium, valpromide;
- neuroleptics such as thioxanthen, pimozide, loxapine, carpipramine, phenothiazine derivatives such as chlorpromazine, thioridazine, fluphenazine, butyrophenone derivatives such as haloperidol, penfluridol, pipamperone, benperidol, benzamide derivatives such as sulpiride, amisulpiride, tiapride, sultopride;
- antimetabolites such as methotrexate, mercaptopurine, fluorouracil, cytarabine, hydroxo-urea, asparaginase;
- alkylating agents such as busulfan, pipobroman, procarbazine, nitrogen mustard derivatives such as chlorambucil, cyclophosphamide, estramustine, melphalan, lomustine, fotemustine;
- anticancer steroids such as methoxyprogesterone, gestonorone, norethisterone, diethylstilbestrol, dienestrol;
- and more generally peptides having a therapeutic activity.

A pharmaceutically acceptable salt of any one of the salifiable active ingredients listed above may also be selected as active ingredient.

The content of active ingredient in the first layer will be determined according to the pathology to be treated.

This content may be high, it being possible for the active substance to represent up to 99.0% of the total weight of the first layer, and for example from 1

- 9 -

to 99.0% by weight, preferably from 85 to 95% of the total weight of the first layer.

The second layer may contain up to 98.5% by weight of active ingredient, for example from 1 to 95% by weight, better still from 60 to 80%.

Numerous immediate-release compositions are known in the art and persons skilled in the art may thereby be freely inspired for the production of the first layer.

Persons skilled in the art will choose in particular the constituents of the first layer so as to ensure rapid disintegration thereof upon contact with water or with a physiological fluids.

It is in particular known to incorporate into this type of layer a disintegrating agent whose role is to cause the disintegration of the tablet in the presence of water or of physiological fluids.

These disintegrating agents are normally included in the said layer in an amount of from 0 to 15% by weight, preferably from 2 to 5% by weight. Examples of such disintegrating agents are: alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, anhydrous colloidal silica, croscarmellose sodium, crospovidone, guar gum, magnesium and aluminium silicate, methyl cellulose, microcrystalline cellulose, potassium polacrilin, cellulose, pregelatinized starch, sodium alginate, starch sodium glycolate, starch and the effervescent mixtures known in the art for their disintegrating action.

The effervescent mixtures form part of the substances capable of rapidly causing the disintegration of the first layer, especially when the latter comes into contact with the gastric acids. These mixtures generally contain alkali metal or alkaline-earth metal carbonates or bicarbonates or sodium glycine carbonate.

Other additives may be incorporated into the immediate-release layer, such as diluents, binders,

- 10 -

lubricants, antioxidants, colourings, sweeteners, flavourings and acidulants, wetting agents, hydrophilizing agents such as sorbitol and cyclodextrins, osmotic agents such as mannitol, pH  
5 correctors, stabilizing agents such as trehalose and mannitol, adsorbants, chelating and sequestering agents and gastroresistant film-coating excipients of the type including cellulose acetylphthalate and polymethacrylates.

10 By way of example, there may be chosen any one of the following diluents or alternatively a combination thereof: calcium carbonate, calcium sulfate, sucrose, dextrans, dextrin, dextrose, dicalcium phosphate dihydrate, kaolin, magnesium  
15 carbonate, magnesium oxide, maltodextrin, cellulose, microcrystalline cellulose, sorbitol, starches, pregelatinized starch, talc, tricalcium phosphate and lactose.

Among the binders, there may be mentioned: gum  
20 arabic, gum tragacanth, guar gum, alginic acid, sodium alginate, sodium carboxymethylcellulose, dextrin, gelatin, hydroxyethylcellulose, hydroxypropylcellulose, liquid glucose, magnesium and aluminium silicate, maltodextrin, povidone, pregelatinized starch, starch  
25 and zein.

The lubricants are glidants (such as anhydrous colloidal silica, magnesium trisilicate, magnesium silicate, cellulose, starch, talc or tricalcium phosphate) or alternatively antifriction adhering  
30 agents (such as calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oils, paraffin, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, fumaric acid, stearic acid or zinc stearate  
35 and talc).

As examples of antioxidants, persons skilled in the art may select any of the following compounds: ascorbic acid, ascorbyl palmitate, fumaric acid, propyl

- 11 -

gallate, sodium ascorbate and sodium metabisulfite, alpha-tocopherol, malic acid, BHA and BTH.

Preferred wetting agents are:

- sodium docusate and sodium lauryl sulfate  
5 which are anionic surfactants;
- benzalkonium chloride, benzethonium chloride and cetrimide which are cationic surfactants;
- glyceryl monooleate, fatty acid esters of polyoxyethylene sorbitan, poly(vinyl alcohol) and  
10 sorbitans, which are nonionic surfactants.

Among the pH regulators, there are acidifying agents of the type including citric acid, hydrochloric acid, lactic acid, tartaric acid, as well as  
alkalinizing agents of the type including  
15 monoethanolamine, diethanolamine and triethanolamine, potassium citrate, sodium bicarbonate, sodium citrate dihydrate.

Examples of adsorbents are bentonite, anhydrous colloidal silica, kaolin, magnesium and aluminium  
20 silicate, microcrystalline cellulose and cellulose.

As chelating and sequestering agents, there may be used citric acid monohydrate, edetic acid, disodium phosphate, monosodium phosphate, potassium citrate, tartaric acid and sodium citrate dihydrate.

25 The quantities of these additives are those normally used in the art. Generally, the binder may represent from 0.5 to 25% by weight, better still from 2 to 5% by weight of the said first layer.

The lubricants are preferably incorporated into  
30 this first layer in an amount of 0.01 to 10% by weight.

As a guide, the quantity of gastroresistant film-coating excipients varies between 0.5 and 9% by weight.

It will be noted that all the abovementioned  
35 additives, with the exception of the disintegrating agents may also be added to the prolonged-release layer in similar proportions. The prolonged-release layer may, in addition, contain diluents chosen from glyceryl palmitostearate, hydrogenated vegetable oils,

- 12 -

polymethacrylates, potassium chloride and sodium chloride.

Moreover, binders such as carbomer, ethyl cellulose, hydrogenated vegetable oils, 5 hydroxypropylmethylcellulose, methyl cellulose and polymethacrylates may be incorporated into the prolonged-release layer.

However, the essential constituents of the second prolonged-release layer are polymeric materials 10 which confer on it its inert and nonbiodegradable character. According to the invention, the polymeric materials in question are polymers or copolymers insoluble in water (but not forming a gel either upon immersion in an aqueous medium) which are discharged 15 intact by the body.

These polymers may play the role of binder in the composition of the second layer.

Such materials are in particular polyvinyl chlorides, vinyl acetate/vinyl chloride copolymers, 20 acrylonitrile/vinylidene chloride copolymers, polydimethylsiloxanes and copolymers derived from (meth)acrylic acids.

The copolymers derived from (meth)acrylic acids comprise the copolymers of derivatives of methacrylic 25 acid and the copolymers of derivatives of acrylic acid and of derivatives of methacrylic acid. As derivatives of (meth)acrylic acids, esters are preferred.

According to a preferred embodiment of the invention, the nonbiodegradable inert polymeric 30 material is chosen from the groups consisting of ethyl acrylate and methyl methacrylate copolymers, ethylammonium methacrylate and methyl acrylate copolymers, ethylammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and 35 methyl methacrylate copolymers, ethylammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers, methacrylic acid and methyl methacrylate copolymers.

- 13 -


According to the invention, "ethylammonium" is understood to mean a radical chosen from the ammonioethyl, (C<sub>1</sub>-C<sub>4</sub>)alkylammonioethyl, di(C<sub>1</sub>-C<sub>4</sub>)alkylammonioethyl and tri(C<sub>1</sub>-C<sub>4</sub>)alkylammonioethyl groups.

5 Preferably, ethylammonium designates a trimethylammonioethyl radical.

Such materials are commercially available, for example, from the company Röhm.

There may be mentioned, purely as a guide:


10 - the copolymers Eudragit RL 30 D<sup>®</sup>, Eudragit RS 30 D<sup>®</sup>, Eudragit RL PO<sup>®</sup> and Eudragit RS PO<sup>®</sup>, Eudragit RL 12.5<sup>®</sup>, Eudragit RS 12.5<sup>®</sup>, Eudragit RL 100<sup>®</sup> and Eudragit RS 100<sup>®</sup>, which are copolymers of esters of acrylic acid and of esters of methacrylic acid, with a low content  
15 of ammonium groups. These polymers have as recurring unit:



20 in which R<sub>1</sub> is a hydrogen atom or a methyl group and R<sub>2</sub> is the methyl or ethyl group;

- the copolymer Eudragit NE 30 D<sup>®</sup> which is a neutral copolymer of ethyl acrylate and methyl methacrylate, in which the recurring unit has the formula:


25



- 14 -


- the copolymers Eudragit L 30 D-55<sup>®</sup> and Eudragit L100-55<sup>®</sup> which are copolymers of methacrylic acid and ethyl acrylate, in which the recurring unit has the formula:

5



- the copolymers Eudragit L 100<sup>®</sup>, Eudragit L 12.5<sup>®</sup>, Eudragit S 100<sup>®</sup> and Eudragit S 12.5<sup>®</sup> which are copolymers of methacrylic acid and methyl methacrylate in which the recurring unit has the formula:

10



15 Among these polymers, the copolymer NE 30 D<sup>®</sup> has proved particularly advantageous. In general, the copolymers of esters of methacrylic acid and of esters of acrylic acid are used in preference to any other type of inert matrix.

20 The molecular mass of the polymeric material used may vary to a large extent depending on the nature of the monomers constituting the material.

In the case of the copolymers derived from acrylic and/or methacrylic acid mentioned above, the average molecular mass is between 100,000 and 1,000,000, preferably between 130,000 and 800,000.

25 It is desirable that the quantity of inert polymeric materials does not exceed 25% of the total weight of the second layer, and is not less than 1% of the total weight of this layer. Preferably, the

30



- 15 -

quantity of polymeric materials varies between 2.5% and 12% of the total weight of the second layer.

The whole tablet may be coated with a gastroresistant or enterosoluble polymeric film, such that the active ingredient is released only in the duodenal tract.

The polymeric substances generally used for the production of the gastroresistant systems are cellulose acetophthalate, cellulose acetopropionate, cellulose trimellitate or polymers and copolymers of (meth)acrylic acids.

The tablets of the invention are conventionally prepared by a method including the steps of granulation, followed by compression.

More precisely, the method of preparation, which is the subject of the invention, comprises the steps consisting in:

a) preparing a granule of a first active substance from a pulverulent mixture of the said first active substance, a disintegrating agent and one or more additives suitable for the preparation of a layer for the immediate release of the said active substance;

b) preparing a granule of a second active substance from a pulverulent mixture of the said second active substance, from one or more nonbiodegradable inert polymeric materials and from one or more additives suitable for the preparation of a layer for the prolonged release of the said active substance;

c) combining, by compressing, in a manner known per se, the two types of granule obtained in steps a) and b) above so as to obtain tablets in which the first layer, affording immediate release, results from the compression of the granule obtained in step a), and, having a second layer arranged in contact with the said first layer, the said second layer resulting from the compression of the prolonged-release granule obtained in step b).

The first step (step a)) is designed to provide a granule based on the first active substance, which

- 16 -

will lead, through compression, to the first layer, called immediate-release layer.

The second step (step b)) is designed to provide a granule based on the same active substance or  
5 on a different active substance, which will lead, through compression, to the second layer, called prolonged-release layer. The constituents of this layer are those of the nonbiodegradable inert polymeric matrix defined above.

10 Step c) leads to the formation of the tablet through successive compression of the granules obtained in the preceding steps a) and b).

Steps a) and b) involve the granulation of powders of amorphous or crystallized particles. This  
15 granulation is carried out in a manner known per se and, for example, by a wet granulation method.

The method of granulation comprises five essential steps: (i) dry-mixing of its various constituents, (ii) wetting, (iii) granulation proper,  
20 (iv) drying, and then (v) sizing.

The dry-mixing consists in mixing the pulverulent excipients entering into the composition of the granule.

The wetting consists in adding to the  
25 pulverulent mixture various constituents, a wetting liquid which may be water, a (C<sub>1</sub>-C<sub>4</sub>)alkanol, an aqueous solution of binder or an alcoholic solution of binder. According to the invention, the expression "alcoholic solution of binder" includes both the alcoholic and  
30 aqueous-alcoholic solutions in which the solvent is a mixture of one or more (C<sub>1</sub>-C<sub>4</sub>)alkanols or a mixture of water and of one or more (C<sub>1</sub>-C<sub>4</sub>)alkanols. A preferred (C<sub>1</sub>-C<sub>4</sub>)alkanol is isopropanol. It is carried out in a kneading, planetary, mixing pan, projection or  
35 whirling-type mixer-blender or a rapid-type mixer-granulator.

In step a), the appropriate wetting liquid is water, a (C<sub>1</sub>-C<sub>4</sub>)alkanol, an aqueous solution of binder

- 17 -

or an alcoholic solution of binder as defined above, and as generally recommended in the art.

In step b), it is possible to use an aqueous dispersion or an organic solution of the nonbiodegradable polymeric material(s) as wetting liquid. Better homogeneity of distribution of the matrix is thus obtained. "Organic solution" is understood according to the invention to mean a solution of the nonbiodegradable polymeric material(s) in an organic solvent which is either a mixture of one or more (C<sub>1</sub>-C<sub>4</sub>)alkanols, or a mixture of one or more ((C<sub>1</sub>-C<sub>4</sub>)alkyl)((C<sub>1</sub>-C<sub>4</sub>)alkyl)ketones and of one or more (C<sub>1</sub>-C<sub>4</sub>)alkanols. According to the invention, isopropanol is the preferred (C<sub>1</sub>-C<sub>4</sub>)alkanol. Likewise, when a mixture of ketone(s) and of alkanol(s) is used, the mixture of isopropanol and acetone is preferred.

When the polymeric material is a copolymer derived from acrylic and/or methacrylic acid, the dispersion or the solution will preferably have a viscosity of between 10 and 300 mPa.s, better still between 15 and 200 mPa.s.

According to a preferred embodiment of the invention, the sizing is carried out by passing over a screen with a mesh opening of between 0.5 and 1.5 mm, preferably of between 0.8 and 1.5 mm.

The preferred value of the mesh opening is 1.25 mm in each of steps a) and b).

However, the invention is not limited to carrying out a wet granulation method. Thus, persons skilled in the art will also be able to use the other existing granulation methods, such as the dry granulation method.

The last step (step c)) leads to the formation of the tablet. The combination of the granules is carried out in a conventional manner using the granules obtained in steps a) and b).

In the case of bilayer tablets, containing concentric layers, this step involves (i) compression, in a first compression chamber, of the entire

- 18 -

prolonged-release granule obtained in step b) for the production of a core tablet; (ii) the compression, in a second compression chamber, of a portion, preferably 50% by weight, of the immediate-release granule obtained in step a) above; (iii) the introduction and the positioning of the core tablet resulting from step (i) above in the said second compression chamber; (iv) the application of a gentle compression with centring of the core in the said second compression chamber; (v) the addition of the remainder of the immediate-release granule to the said second granulation chamber; and (vi) the conjoint compression of the immediate-release granule on the tablet formed in step iv) above.

In the case of bilayer tablets, containing parallel layers, step c) comprises: (i) a gentle compression of the entire prolonged-release granule in a compression chamber; and then (ii) the addition of the entire immediate-release granule to the said compression chamber and its positioning on the tablet resulting from step i) above; and (iii) the final compression of the tablet.

The respective proportions of the immediate-release and prolonged-release granules are not critical according to the invention.

The tablets of the invention may be administered by the oral or vaginal route. They allow the immediate release of a first active substance, and then the release of a second active substance, which is optionally identical to the first, over a period of 2 to 12 h.

The multilayer tablets of the invention are particularly advantageous since their method of preparation is simple, the excipients constituting them being customary. Furthermore, it is possible, by appropriately selecting the nonbiodegradable inert polymeric materials, to vary the dissolution profiles to a very large extent and with precision, depending on the needs.

- 19 -

According to the preferred embodiment of the invention, the polymeric materials belong to the Eudragit series marketed by the company Röhm, which are copolymers derived from methacrylic and/or acrylic acid. Because of the diversity of the properties of these copolymers, it is possible to obtain modulation of the release profile of the active ingredients.

In addition, these copolymers confer on the resulting tablets excellent formulation capacity (possibility of incorporating high levels of active ingredients) and compression capacity.

The choice of such copolymers offers, in addition, the possibility of film-coating the tablets with excipients of the Eudragit type in order to obtain a gastroresistant coating.

On the other hand, these copolymers are absolutely inert in relation to the body, which ensures release of the active ingredient independently of the influence of the body (and in particular of pH variations) and therefore reliability, safety, quality, reproducibility and better tolerance of the effects linked to the administration of the tablets of the invention.

The examples provided in the text which follows illustrate the invention more clearly. Reference will be made to the accompanying Figures 1 and 2.

#### **EXAMPLE 1**

##### **a) Preparation and formulation of the immediate-release granule**

The active ingredient is 2-ethoxymethyl-4(3H)-pteridinone, designated as EMP in the text which follows.

The constituents for the preparation of the immediate-release granule, designated as GLI-1 in the text which follows, were used in the following proportions by weight:

EMP	94.12%
Polyvinylpyrrolidone 30	2.94%

- 20 -

Cross-linked carboxymethylcellulose	<u>2.94%</u>
Total	100.00%

5 The active ingredient, polyvinylpyrrolidone 30, and the carboxymethylcellulose are introduced into a mixer-granulator for a 3-minute mixing.

The wetting liquid, osmosed water, is then introduced into the mixer-granulator until well-formed grains and agglomerates are obtained. Next, the whole  
10 is dried (oven or fluidized air bed) and sized on a screen with a mesh opening of 1.25 mm.

**b) Preparation and formulation of the prolonged-release granule**

15 The active ingredient is that used in Example 1.

The nonbiodegradable polymeric material used is Eudragit NE 30 D<sup>®</sup> marketed by the company Röhm.

The constituents for the preparation of the prolonged-release granule, designated as GLP-1 in the  
20 text which follows, were used in the following proportions by weight:

EMP	71.70%
Fine lactose powder	17.20%
Eudragit NE 30 D <sup>®</sup>	8.80%
25 Talc	1.10%
Magnesium stearate	<u>1.20%</u>
Total	100.00%

30 The active ingredient and the lactose are introduced into a mixer-granulator for a 3-minute mixing.

The Eudragit NE 30 D<sup>®</sup>, which is an aqueous dispersion of a neutral copolymer of ethyl acrylate and methyl methacrylate, is then gradually introduced into  
35 the mixture, as wetting liquid. Purified water is added, if necessary, in order to obtain well-formed granules comprising agglomerates. Next, the granule is dried in a fluidized air bed and sized on a screen with a mesh opening of 1.25 mm. The lubricants (talc and

- 21 -

magnesium stearate) are then mixed with the granule obtained above for 40 seconds.

**c) Preparation of tablets containing concentric layers and of so-called tablets containing parallel layers**

The following tablets containing parallel layers A to D are obtained using the following steps by means of a compressing machine provided with ovoid dies:

(i) by gentle compression, in a compression chamber, of the entire prolonged-release granule of Example 1b); and

(ii) by addition, in the same compression chamber, of the entire immediate-release granule of Example 1a) over the tablet obtained in step (i); and

(iii) by subsequent compression of the whole consisting of the immediate-release granule of Example 1a) and of the tablet obtained in step (i) above.

The following tablet containing concentric layers E was obtained using the following steps:

(a) the compression, in a first compression chamber, of the entire prolonged-release granule of Example 1b) for the production of a core tablet;

(b) the compression of a fraction of the immediate-release granule of Example 1a) in a second compression chamber (about half);

(c) the transfer of the tablet resulting from step (a) into the second compression chamber;

(d) the application of a gentle compression with centring of the tablet of step (a) in the said second compression chamber;

(e) the addition of the remainder of the immediate-release granule of Example 1a) to the second compression chamber, and

(f) the conjoint compression of the immediate-release granule of Example 1a) and of the tablet resulting from step (d) above.

Table 1 below indicates, for each tablet, the respective quantities of granules used.

TABLE 1

Tablet (reference)	Quantity of GLI granules (mg)	Quantity of GLP granules (mg)	Unit weight of the tablet (mg)
A	425.0	558.0	983.0
B	531.2	697.5	1228.7
C	318.7	976.3	1295.0
D	318.7	697.5	1016.2
E	531.2	558.0	1089.2

**EXAMPLE 2****Dissolution profiles for the tablets  
5 manufactured according to the procedure of Example 1**

The dissolution profiles for the tablets manufactured in the preceding example were determined by UV spectrometry.

10 The tablet to be tested is introduced into a reactor previously charged with one litre of osmosed water, at 37°C, and provided with a temperature-regulating system and with an effective stirring system.

15 During the whole experiment, the reactor is kept stirring at 37°C.

At regular intervals of time  $t$ , samples of the medium contained in the reactor are collected, filtered on a filter with a porosity of 0.45  $\mu\text{m}$ , and analysed by UV spectrometry.

**20 Conditions for analysis by UV spectrometry:**

The optical density of the samples collected, diluted in a known volume of osmosed water, is measured at 313 nm.

25 The quantity of active ingredient  $q$  present in the sample is determined by comparison with the optical density of a control solution of the active ingredient, EMP, of known concentration. A simple calculation makes it possible to find the total quantity of active ingredient released in the reactor at the instant  $t$ .

30 The dissolution profile for a tablet tested is obtained by plotting, on a curve, the calculated



- 23 -

quantities of active ingredient as a function of the time of collection.

The accompanying Figures 1 and 2 show the dissolution profiles plotted in the cases of tablets A to E above.

**EXAMPLE 3**

By following the operating protocol described in Example 1, the tablets containing parallel layers F to I in the following Table 2 are prepared:

TABLE 2

Tablet	Type of immediate-release granules	Quantity of immediate-release granules (mg)	Type of prolonged-release granules	Quantity of prolonged-release granules (mg)
F	GLI-2	327.9	GLP-2	836.8
G	GLI-2	546.4	GLP-3	697.35
H	GLI-2	327.9	GLP-4	697.35
I	GLI-2	437.15	GLP-4	557.9

The formulation of the immediate-release granules, GLI-2, is given below:

EMP	91.5%
Polyvinylpyrrolidone 30	4.0%
Cross-linked carboxymethylcellulose	4.0%
Magnesium stearate	<u>0.5%</u>
TOTAL	100%

These granules are prepared using the operating protocol of Example 1a).

The formulations of the prolonged-release granules are given below:

25 GLP-2

EMP	71.7%
Fine lactose powder	16%
Eudragit RSPO	10%
Talc	1.1%
Magnesium stearate	<u>1.2%</u>
TOTAL	100%

- 24 -

GLP-3

	EMP	71.7%
	Fine lactose powder	17.2%
	Eudragit RS30D	8.8%
5	Talc	1.1%
	Magnesium stearate	<u>1.2%</u>
	TOTAL	100%

GLP-4

	EMP	71.7%
10	Fine lactose powder	17.2%
	Eudragit RSPO	8.8%
	Talc	1.1%
	Magnesium stearate	<u>1.2%</u>
	TOTAL	100%

15

These granules are prepared using the operating protocol of Example 1b).

**EXAMPLE 4**

20 The dissolution curves for tablets F to I were plotted using the operating protocol described in Example 2.

These curves are presented in Figures 3 to 6.

- 25 -

**CLAIMS**

1. Multilayer tablet for the instant and then prolonged release of active substances comprising at  
5 least two superposed layers, characterized in that:

- a first outer layer is composed of a mixture of excipients and of a first active substance, the said first layer allowing immediate release of the said first active substance;

10 - a second layer, arranged in contact with the said first layer, consists of a nonbiodegradable, inert porous polymeric matrix in which a second active substance is dispersed.

2. Tablet according to Claim 1, characterized in  
15 that the second active substance is identical to the first active substance.

3. Tablet according to any one of the preceding claims, characterized in that the nonbiodegradable inert polymeric matrix contains one or more  
20 nonbiodegradable inert polymeric materials chosen from polyvinyl chlorides, vinyl acetate/vinyl chloride copolymers, copolymers derived from acrylic and/or methacrylic acids, acrylonitrile/vinylidene chloride copolymers and polydimethylsiloxanes.

25 4. Tablet according to Claim 3, characterized in that the copolymers derived from methacrylic and/or acrylic acids are chosen from the groups consisting of copolymers of esters of ethyl acrylate and methyl methacrylate, ethylammonium methacrylate and methyl  
30 acrylate copolymers, ethylammonium methacrylate and ethyl acrylate copolymers, ethylammonium methacrylate and methyl methacrylate copolymers, ethylammonium methacrylate and ethyl methacrylate copolymers, methacrylic acid and ethyl acrylate copolymers,  
35 methacrylic acid and methyl methacrylate copolymers.

5. Tablet according to either of Claims 3 and 4, characterized in that the nonbiodegradable inert polymeric materials are present in the said second layer in an amount of 1 to 25% by weight.

- 26 -

6. Tablet according to any one of the preceding claims, characterized in that the porous polymeric matrix comprises from 1 to 95% by weight of the said second active substance.
- 5 7. Tablet according to any one of the preceding claims, characterized in that the said first layer comprises one or more disintegrating agents chosen from alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, anhydrous colloidal  
10 silica, croscarmellose sodium, crospovidone, guar gum, magnesium and aluminium silicate, methyl cellulose, microcrystalline cellulose, potassium polacrilin, cellulose, pregelatinized starch, sodium alginate, starch sodium glycolate, starch and the effervescent  
15 mixtures known in the art for their disintegrating action.
8. Tablet according to any one of the preceding claims, characterized in that the said first layer comprises from 1 to 99.0% by weight of the said first  
20 active substance.
9. Bilayer tablet according to any one of the preceding claims, characterized in that the said second layer has a top surface and a bottom surface, only one of the said surfaces being in contact with the said  
25 first layer.
10. Bilayer tablet according to any one of the preceding claims, characterized in that the said first layer and the said second layer are concentric.
11. Method for preparing a tablet according to any  
30 one of Claims 1 to 10, comprising the steps consisting in:
- a) preparing a granule of a first active substance from a pulverulent mixture of the said first active substance, a disintegrating agent and one or  
35 more additives suitable for the preparation of a layer for the immediate release of the said active substance;
  - b) preparing a granule of a second active substance from a pulverulent mixture of the said second active substance, from one or more nonbiodegradable


- 27 -

inert polymeric materials and from one or more additives suitable for the preparation of a layer for the prolonged release of the said active substance;


5 c) combining, by compressing, in a manner known per se, the two types of granule obtained in steps a) and b) above so as to obtain tablets in which the first layer, affording immediate release, results from the compression of the granule obtained in step a), and, having a second layer arranged in contact with the said  
10 first layer, the said second layer resulting from the compression of the granule obtained in step b).



12. Tablet according to any one of Claims 1 to 10, characterized in that the said second layer comprises, as active substance, 2-ethoxymethyl-4(3H)-pteridinone.

1/4

FIG. 1



2/4

FIG. 2

**FIG.3****FIG.4**



4/4

FIG.5FIG.6

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/08100

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 359 483 A (ISAO KAETSU, ET AL.) 16 November 1982 see claim 1 see column 1, line 50 - column 2, line 15 see column 2, line 38 - line 52 see column 2, line 64 - column 3, line 17 ---	1-6,8-11
X	EP 0 169 821 A (SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE) 29 January 1986 see claims 1,8,9,11,12 see page 10, line 1 - line 13 see page 13, line 23 - page 14, line 17 ---	1,2,6,8, 10,11
A	FR 2 645 152 A (LIPHA) 5 October 1990 see the whole document -----	12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 April 1999

Date of mailing of the international search report

09/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/08100

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4359483 A	16-11-1982	JP 1239339 C	13-11-1984
		JP 56120618 A	22-09-1981
		JP 59011563 B	16-03-1984
		DE 3106984 A	18-02-1982
EP 169821 A	29-01-1986	AT 60709 T	15-02-1991
		AU 578299 B	20-10-1988
		AU 4525185 A	30-01-1986
		BR 8503539 A	22-04-1986
		DK 339385 A	27-01-1986
		EG 17763 A	30-08-1990
		FI 852894 A,B,	27-01-1986
		GR 851844 A	02-12-1985
		IE 58120 B	14-07-1993
		IN 162047 A	19-03-1988
		JP 61043109 A	01-03-1986
		MX 173488 B	08-03-1994
		PH 22507 A	12-09-1988
		PT 80865 B	18-09-1987
		US 4681755 A	21-07-1987
FR 2645152 A	05-10-1990	AT 126229 T	15-08-1995
		AU 630178 B	22-10-1992
		AU 5221890 A	04-10-1990
		CA 2013324 A	30-09-1990
		CZ 9001520 A	11-11-1998
		DD 296927 A	19-12-1991
		DE 69021444 D	14-09-1995
		DE 69021444 T	14-03-1996
		DK 399856 T	18-09-1995
		EP 0399856 A	28-11-1990
		ES 2078324 T	16-12-1995
		GR 3017245 T	30-11-1995
		HR 920759 A	30-06-1995
		HU 208826 B	28-01-1994
		IE 68689 B	10-07-1996
		IL 93914 A	27-02-1994
		JP 1994320 C	22-11-1995
		JP 2304089 A	17-12-1990
		JP 7025761 B	22-03-1995
		LV 5821 B	20-10-1997
		LV 5821 A	20-04-1997
		NO 175100 B	24-05-1994
		OA 9441 A	15-10-1992
		PT 93600 A,B	20-11-1990
		SI 9010633 A	28-02-1997
		SU 1836344 A	23-08-1993
		US 5167949 A	01-12-1992
		US 5270465 A	14-12-1993